MyFinsight
Home
Blog
About
Proceeds from issuance of
series b preferred...
$2,000,000
Transaction costs from
public offerings
-$204,193
(-200.00%↓ Y/Y)
Net cash provided by
financing activities
$1,893,680
(-39.38%↓ Y/Y)
Canceled cashflow
$310,513
Decrease in cash and cash
equivalents
-$68,778
(94.67%↑ Y/Y)
Canceled cashflow
$1,893,680
Consultant compensation
$646,310
(218.36%↑ Y/Y)
Accrued expenses and
other liabilities
$312,856
(-11.07%↓ Y/Y)
Accounts payable
$308,467
(198.16%↑ Y/Y)
Depreciation expense
$6,533
Stock-based compensation
$1,870
(-98.25%↓ Y/Y)
Accrued interest
$320
(-94.76%↓ Y/Y)
something is missing
-$204,193
Transaction costs
associated with series b...
$106,320
Net cash used in
operating activities
-$1,962,458
(55.54%↑ Y/Y)
Canceled cashflow
$1,276,356
Net loss
-$2,570,875
(30.12%↑ Y/Y)
Unbilled receivable
$416,811
(-61.44%↓ Y/Y)
Prepaid expenses and
other assets
$251,128
(21292.24%↑ Y/Y)
Back
Back
Cash Flow
Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. (ENSC)
source: myfinsight.com